W poniższej części podsumowano spostrzeżenia na temat następującego miernika spółki Alteogen Inc — Opis:
Wartość opis spółki Alteogen wynosi ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; and Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Punkty odniesienia
Ukryj ten widżet
Brak danych
Użycie miernika: Opis
Ukryj ten widżet
Oznaczenie
description
Typ danych
Treść
Format
tekst
Domyślny okres
bieżące
Plan
Za darmo
Pełna lista obsługiwanych wskaźników finansowych znajduje się w sekcji Pełna lista mierników.
Press space bar to start a drag.
When dragging you can use the arrow keys to move the item around and escape to cancel.
Some screen readers may require you to be in focus mode or to use your pass through key